DNA

CDC Traveler-based Genomic Surveillance Program to Expand to Two New US International Airports in Miami and Chicago

Retrieved on: 
Tuesday, March 12, 2024
Miami International Airport, Genomics, Federation, Traveler, Pneumonia, JFK, Mycoplasma pneumoniae, Partnership, COVID-19, DNA, MIA, Bacteria, SARS-CoV-2, RSV, Ginkgo Bioworks, Biosecurity, Mycoplasma, CDC, Airport, TGS, Collection, Federal, Vaccine

This expanded funding will also bring the number of airports in the program to a total of nine active sites: Los Angeles, San Francisco, New York (JFK), Washington Dulles, Newark, Boston, Seattle, Miami, and Chicago.

Key Points: 
  • This expanded funding will also bring the number of airports in the program to a total of nine active sites: Los Angeles, San Francisco, New York (JFK), Washington Dulles, Newark, Boston, Seattle, Miami, and Chicago.
  • Since its inception in September 2021, the TGS program has demonstrated its ability to serve as an early detection mechanism for new pathogens and fill gaps in global biosurveillance.
  • In October 2023, the program expanded to cover a list of more than 30 viral and bacterial targets.
  • “We are thrilled to have the opportunity to take the TGS program to the next level.

Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations

Retrieved on: 
Tuesday, March 12, 2024
Health, Union, Congress, DNA, Standard of care, Cancer, UDH, CRC, German, Pharmaceutical industry

Mainz Biomed’s showcase at the UDH Congress underscores the Company’s dedication to bridging the latest in scientific research with the wide spectrum of healthcare practices.

Key Points: 
  • Mainz Biomed’s showcase at the UDH Congress underscores the Company’s dedication to bridging the latest in scientific research with the wide spectrum of healthcare practices.
  • ColoAlert®, Mainz Biomed’s flagship product, is a testament to the Company’s mission, providing a highly accurate, easy-to-use, at-home colorectal cancer (CRC) screening kit.
  • By presenting ColoAlert® at the UDH Congress, Mainz Biomed highlights the role of cutting-edge molecular diagnostics in enhancing comprehensive health strategies, demonstrating the synergy between technological innovation and patient-centric care.
  • For more details on Mainz Biomed’s participation in the UDH Congress and to learn about the Company’s innovative diagnostic solutions, please visit Mainz Biomed’s official website at mainzbiomed.com.

Tempus Announces 18 Abstracts Accepted For Presentation at the American Association for Cancer Research Annual Meeting 2024

Retrieved on: 
Friday, April 5, 2024
Research, Managed Care, Pharmaceutical, Oncology, Data Management, Technology, Artificial Intelligence, Genetics, Health Technology, Science, Biotechnology, Health, Mutation, Survival, ESR1, Intelligence, Progression-free survival, Patient, NGS, DNA, MD, Medicine, Abstract, AACR, TRM, Clonal hematopoiesis, AIS, Liquid biopsy, Enzyme inhibitor, Annual general meeting, Medical imaging

Tempus, a leader in artificial intelligence and precision medicine, today announced 18 abstracts were accepted for presentation at the 2024 American Association for Cancer Research (AACR) Annual Meeting, which convenes from April 5-10, in San Diego, California.

Key Points: 
  • Tempus, a leader in artificial intelligence and precision medicine, today announced 18 abstracts were accepted for presentation at the 2024 American Association for Cancer Research (AACR) Annual Meeting, which convenes from April 5-10, in San Diego, California.
  • Tempus researchers will demonstrate how the company’s AI-enabled precision medicine platform collects and analyzes high-quality, multimodal datasets to advance cancer research.
  • “We look forward to presenting 18 abstracts at AACR this year, demonstrating the breadth and depth of our research both at Tempus and with our biopharma collaborators,” said Ezra Cohen, MD, Chief Medical Officer, Oncology at Tempus.
  • These preliminary findings suggest that xM used for TRM can identify patients with ESR1m and poor response on AI who may benefit from switching therapy.

MAIA Biotechnology to Present at Two Investor Conferences in April 2024

Retrieved on: 
Friday, April 5, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Lung cancer, Trial of the century, MAIA, FDA, DNA, Clinical trial, News, NSCLC, Pharmaceutical industry

Participants should refer to the final program agendas for up-to-date information.

Key Points: 
  • Participants should refer to the final program agendas for up-to-date information.
  • MAIA’s lead candidate is THIO, a small molecule telomere-targeting anticancer agent that acts by producing direct telomeric DNA damage and inducing cancer-specific immune responses.
  • Recent news from MAIA’s THIO-101 trial includes:
    Early completion of enrollment; topline data expected in second half of 2024; ( press release, February 22, 2024 )
    Strong response rate of 38% in third-line treatment efficacy data; ( press release, March 6, 2024 ).
  • Multiple paths to potential commercial approval of THIO under consideration; MAIA anticipates a final FDA decision on THIO in 2026; ( MAIA Shareholder Letter 2024 ).

Charles River to Perform Plasmid Production for Ship of Theseus

Retrieved on: 
Thursday, April 4, 2024
Research, Medical Devices, Genetics, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Diabetes, Neutropenia, CDMO, Psoriasis, Infertility, Cancer, MCB, Tissue, CRL, DNA, Pattern hair loss, HOX, Ship, Acquisition, Factorization of polynomials, Display resolution, GMP, Good manufacturing practice, Tecmar, Therapy, HQ, Vaccine

Charles River Laboratories International, Inc. (NYSE: CRL) and Ship of Theseus , a therapeutics company developing degradation-resistant homeobox (HOX) family biologics, today announced a Good Manufacturing Practice- (GMP) plasmid DNA contract development and manufacturing organization (CDMO) agreement.

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) and Ship of Theseus , a therapeutics company developing degradation-resistant homeobox (HOX) family biologics, today announced a Good Manufacturing Practice- (GMP) plasmid DNA contract development and manufacturing organization (CDMO) agreement.
  • Ship of Theseus will leverage Charles River’s premier expertise to manufacture GMP plasmid DNA to serve as the active drug substance for its lead candidate.
  • Charles River’s GMP plasmid DNA CDMO center of excellence based in Keele, United Kingdom will lead the collaboration, providing services that include plasmid DNA backbone generation, plasmid synthesis, GMP master cell bank (MCB) generation, pre-production evaluation, and GMP plasmid DNA manufacture including in-house release testing.
  • We trust the team’s decades of success developing, producing, and reliably delivering plasmid DNA and look forward to bringing our therapies to patients.” – Jeremy Elser, Founding CEO, Ship of Theseus

Charles River to Perform Plasmid Production for Ship of Theseus

Retrieved on: 
Thursday, April 4, 2024
Health, Medical Devices, Stem Cells, Genetics, General Health, Pharmaceutical, Biotechnology, Diabetes, Neutropenia, CDMO, Psoriasis, Infertility, Cancer, MCB, Tissue, CRL, DNA, Research, Pattern hair loss, HOX, Ship, Acquisition, Factorization of polynomials, Display resolution, GMP, Good manufacturing practice, Tecmar, Therapy, HQ, Vaccine

Charles River Laboratories International, Inc. (NYSE: CRL) and Ship of Theseus , a therapeutics company developing degradation-resistant homeobox (HOX) family biologics, today announced a Good Manufacturing Practice- (GMP) plasmid DNA contract development and manufacturing organization (CDMO) agreement.

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) and Ship of Theseus , a therapeutics company developing degradation-resistant homeobox (HOX) family biologics, today announced a Good Manufacturing Practice- (GMP) plasmid DNA contract development and manufacturing organization (CDMO) agreement.
  • Ship of Theseus will leverage Charles River’s premier expertise to manufacture GMP plasmid DNA to serve as the active drug substance for its lead candidate.
  • Charles River’s GMP plasmid DNA CDMO center of excellence based in Keele, United Kingdom will lead the collaboration, providing services that include plasmid DNA backbone generation, plasmid synthesis, GMP master cell bank (MCB) generation, pre-production evaluation, and GMP plasmid DNA manufacture including in-house release testing.
  • We trust the team’s decades of success developing, producing, and reliably delivering plasmid DNA and look forward to bringing our therapies to patients.” – Jeremy Elser, Founding CEO, Ship of Theseus

Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer

Retrieved on: 
Friday, April 5, 2024
Surgery, Genetics, Clinical Trials, Health Technology, Biotechnology, Other Health, Health, Pharmaceutical, Oncology, Congress, Cystectomy, CDX, Patient, Roche, DNA, DFS, EAU, Bladder cancer, MIBC, NTRA, Survival rate, MRD, FDA, Food, Pharmaceutical industry

The analysis evaluates outcomes in muscle-invasive bladder cancer (MIBC) patients who tested serially negative with Signatera™, Natera’s personalized and tumor-informed molecular residual disease (MRD) test.

Key Points: 
  • The analysis evaluates outcomes in muscle-invasive bladder cancer (MIBC) patients who tested serially negative with Signatera™, Natera’s personalized and tumor-informed molecular residual disease (MRD) test.
  • Sponsored by Genentech, a member of the Roche group, IMvigor011 is a global, double-blind, randomized, Phase III trial, in which high-risk MIBC patients are serially tested with Signatera for up to 12 months post cystectomy.
  • Patients who test Signatera MRD-positive at any point during the 12-month surveillance window are randomized to the anti-PDL1 atezolizumab (Tecentriq®) vs. placebo.
  • “We believe the results of this trial will further demonstrate how Signatera can help personalize treatment decisions and improve outcomes for bladder cancer patients.

Mission Bio Launches Sample Multiplexing for Tapestri to Unlock Critical Single-Cell Insights for Oncology and Genome Editing Markets

Retrieved on: 
Thursday, April 4, 2024
Health, Hospitals, Genetics, General Health, Clinical Trials, Pharmaceutical, Biotechnology, PCR, Mutation, B cell, DNA, BioLegend, Medicine, Cancer, Hospital, Drug development, Bone marrow, Mission, AOCS, Pathology, Vaccine

Mission Bio , a leader in single-cell multiomic solutions for precision medicine, today introduces sample multiplexing features for the company’s Tapestri Platform.

Key Points: 
  • Mission Bio , a leader in single-cell multiomic solutions for precision medicine, today introduces sample multiplexing features for the company’s Tapestri Platform.
  • Combining multiple samples into a single experiment will help lower this barrier to entry for academic researchers and de-risk the adoption for biopharma.
  • Sample multiplexing by genotyping, unique to Tapestri, uses the genetic information of the relevant variants obtained by bulk next-generation sequencing to distinguish samples.
  • Mission Bio’s multiplexing capabilities make single-cell technology more accessible to the biomedical community and has the potential to dramatically impact patient care in the future.”
    For more information about Tapestri, please visit www.missionbio.com .

Exact Sciences to Provide Mayo Clinic Patients with Individualized Cancer Tumor Information to Inform Treatment

Retrieved on: 
Thursday, April 4, 2024
Research, Professional Services, Data Management, Oncology, Technology, Medical Devices, Genetics, Artificial Intelligence, Health Technology, Data Analytics, Science, Biotechnology, Health, Cloud, Algorithm, Individualized medicine, Exact sciences, Disease, Physician, Risk, Patient, Mayo Clinic, DNA, Cancer, Multimedia, Collection, Medical imaging

Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the launch of an initiative with Mayo Clinic to provide comprehensive genomic profiling and hereditary cancer tests to patients.

Key Points: 
  • Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the launch of an initiative with Mayo Clinic to provide comprehensive genomic profiling and hereditary cancer tests to patients.
  • View the full release here: https://www.businesswire.com/news/home/20240404198461/en/
    Initiative advances precision cancer medicine by bringing comprehensive genomic profiling and hereditary cancer tests to patients at the Mayo Clinic Comprehensive Cancer Center (Graphic: Business Wire)
    “This collaboration supports our mission to help eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment,” said Kevin Conroy , chairman and chief executive officer, Exact Sciences.
  • The Riskguard hereditary cancer test helps patients and their physicians understand the patients' hereditary risk of cancer.
  • “It will also lead to new scientific and clinical discoveries by Mayo Clinic Comprehensive Cancer Center and Mayo Clinic's Center for Individualized Medicine .”
    Patients will consent to have the tests performed and to have the data shared with Mayo Clinic.

Mango Teams up With Victoria Beckham for the Design of a New Capsule Collection

Retrieved on: 
Thursday, April 4, 2024
Fashion, Retail, Consumer, Women, Manufacturing, Specialty, Textiles, Victoria Beckham, Femininity, Multimedia, Collection, Creativity, DNA, Plan, Ecosystem, Elevate

Mango, one of Europe’s leading fashion industry groups, is teaming up with Victoria Beckham to launch a new capsule collection, which will be available internationally on April 23, 2024.

Key Points: 
  • Mango, one of Europe’s leading fashion industry groups, is teaming up with Victoria Beckham to launch a new capsule collection, which will be available internationally on April 23, 2024.
  • Victoria Beckham x Mango has been designed by Victoria Beckham and reflects the essence of the designer's eponymous label, considered the perfect blend of classic British luxury with a subtle contemporary twist, as well as the shared values of both fashion brands, such as quality and femininity.
  • It follows the latest edition in Mango’s Capsule collection, a collection of eventwear for woman differentiated by the quality of its materials and finishes, which was released in March 2024 after being launched in 2023.
  • Since its inception, Mango has a very clear DNA and its own design and style proposal, whose main attribute is a positioning of superior quality to its competitors.